Reversal of immunoparalysis by recombinant human granulocyte-macrophage colony-stimulating factor in patients with severe sepsis - Intensive Care Medicine
- ️Schulte am Esch, Jochen
- ️Fri Feb 21 2003
References
Sorg C (1991) Macrophages in acute and chronic inflammation. Chest 100:173S–175S
Volk HD, Reinke P, Krausch D, Zuckermann H, Asadullah K, Muller JM, Döcke WD, Kox WJ (1996) Monocyte deactivation—rationale for a new therapeutic strategy in sepsis. Intensive Care Med 22:S474–481
Haveman JW, Muller Kobold AC, Tervaert JW, van den Berg AP, Tulleken JE, Kallenberg CG, The TH (1999) The central role of monocytes in the pathogenesis of sepsis: consequences for immunomonitoring and treatment. Neth J Med 55:132–141
Muller Kobold AC, Tulleken JE, Zijlstra JG, Sluiter W, Hermans J, Kallenberg CG, Cohen Tervaert JW (2000) Leukocyte activation in sepsis, correlation with disease state and mortality. Intensive Care Med 26:883–892
Oberhoffer M, Vogelsang H, Russwurm S, Hartung T, Reinhart K (1999) Outcome prediction by traditional and new markers of inflammation in patients with sepsis. Clin Chem Lab Med 37:363–368
Flohe S, Borgermann J, Dominguez FE, Majetschak M, Lim L, Kreuzfelder E, Obertacke U, Nast-Kolb D, Schade FU (1999) Influence of granulocyte-macrophage colony-stimulating factor (GM-CSF) on whole blood endotoxin responsiveness following trauma, cardiopulmonary bypass and severe sepsis. Shock 12:17–24
Williams MA, Kelsey SM, Collins PW, Gutteridge CN, Newland AC (1995) Administration of rHuGM-CSF activates monocyte reactive oxygen species secretion and adhesion molecule expression in vivo in patients following high-dose chemotherapy. Br J Haematol 90:31–40
Williams MA, Kouroumoussis I, Syndercombe-Court D, Hendry L, Newland AC, Kelsey SM (1995) Administration of recombinant human granulocyte-macrophage colony-stimulating factor after chemotherapy regulates the expression and secretion of monocyte tumor necrosis factor (TNF) and TNF receptors p55 and p75. Blood 86:4234–4242
Presneill JJ, Harris T, Stewart AG, Cade JF, Wilson JW (2002).. A randomized phase II trial of granulocyte-macrophage colony-stimulating factor therapy in severe sepsis with respiratory dysfunction. Am J Respir Crit Care Med 166:138–143
Hill AD, Naama HA, Calvano SE, Daly JM (1995) The effect of granulocyte-macrophage colony-stimulating factor on myeloid cells and its clinical applications. J Leukoc Biol 58:634–642
Root RK, Dale DC (1999) Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor: comparisons and potential for use in the treatment of infections in nonneutropenic patients. J Infect Dis 179: S342–352
Ganser A, Seipelt G, Eder M, Geissler G, Ottmann OG, Hess U, Hoelzer D (1992) Treatment of myelodysplastic syndromes with cytokines and cytotoxic drugs. Semin Oncol. 19:95–101
Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, Reinhart CK, Suter PM, Thijs LG (1996) The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 22:707–710
Nebe T (1998) Flow cytometric analysis of immunoparalysis. Clin Lab 44:441–446
Frings DP, Nierhaus A, Montag B, Gutensohn K, Schulte am Esch J (2001) Quantitative assessment of HLA-DR expression on monocytes as a key prognostic marker in SIRS and sepsis (abstract). Crit Care Med 29: S206
Kox WJ, Bone RC, Krausch D, Docke WD, Kox SN, Wauer H, Egerer K, Querner S, Asadullah K, von Baehr R, Volk HD (1997) Interferon gamma-1b in the treatment of compensatory anti-inflammatory response syndrome. A new approach: proof of principle. Arch Intern Med 157:389–393
Bilgin K, Yaramis A, Haspolat K, Tas MA, Gunbey S, Derman O (2001) A randomized trial of granulocyte-macrophage colony-stimulating factor in neonates with sepsis and neutropenia. Pediatrics 107:36–41
Bone RC (1996) Sir Isaac Newton, sepsis, SIRS and CARS. Crit Care Med 24:1125–1128
Livingston DH, Appel SH, Wellhausen SR, Sonnenfeld G, Polk HC Jr (1988) Depressed interferon gamma production and monocyte HLA-DR expression after severe injury. Arch Surg 123:1309–1312
Nierhaus A, Montag B, Frings D, Schulte am Esch J (2000) Initial decrease and sustained depression of HLA-DR expression on monocytes is predictive of outcome in SIRS and sepsis (abstract). Anesthesiology 93: A461
Döcke WD, Randow F, Syrbe U, Krausch D, Asadullah K, Reinke P, Volk DH, Kox WJ (1997) Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat Med 3:678–681
Hubel K, Dale DC, Liles WC (2002) Therapeutic use of cytokines to modulate phagocyte function for the treatment of infectious diseases: current status of granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, macrophage colony-stimulating factor and interferon-gamma. J Infect Dis 185:1490–1501
Mellstedt H, Fagerberg J, Frodin JE, Henriksson L, Hjelm–Skoog AL, Liljefors M, Ragnhammar P, Shetye J, Osterborg A (1999) Augmentation of the immune response with granulocyte-macrophage colony-stimulating factor and other hematopoietic growth factors. Curr Opin Hematol 6:169–175
Williams MA, Withington S, Newland AC, Kelsey SM (1998) Monocyte anergy in septic shock is associated with a predilection to apoptosis and is reversed by granulocyte-macrophage colony-stimulating factor ex vivo. J Infect Dis 178:1421–1433
Perry SE, Mostafa SM, Wenstone R, McLaughlin PJ (2002) Low plasma granulocyte-macrophage colony stimulating factor is an indicator of poor prognosis in sepsis. Intensive Care Med 28:981–984
Trapnell BC (2002) Granulocyte macrophage colony-stimulating factor augmentation in sepsis. Is there a role? Am J Respir Crit Care Med 166:129–130